Compare NHTC & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHTC | BTAI |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 49.2M |
| IPO Year | 1995 | 2018 |
| Metric | NHTC | BTAI |
|---|---|---|
| Price | $2.74 | $2.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 73.9K | ★ 661.6K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 28.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,873,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.40 | $1.17 |
| 52 Week High | $6.00 | $9.26 |
| Indicator | NHTC | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 51.76 |
| Support Level | $2.74 | $1.82 |
| Resistance Level | $3.07 | $2.33 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 18.53 | 62.87 |
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and to support active, physical and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and rest from China, Taiwan, Japan, United States and other regions.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.